Inactive Instrument

PLx Pharma Winddown Corp.

Equities

PLXP

US72942A1079

PLx Pharma Inc. Announces Executive Changes

April 23, 2020 at 02:20 pm

On April 22, 2020, Dr. Efthymios Deliargyris resigned as Chief Medical Officer of PLx Pharma Inc. (the 'Company'), effective April 30, 2020. Dr. Deliargyris’ departure was not in connection with any disagreement relating to the Company’s operations, policies or practices. The Company intends to appoint Dr. Deliargyris as a member of the Company’s Scientific Advisory Board.

Latest news about PLx Pharma Winddown Corp.

PLx Pharma Winddown Corp. Went Out of Business	29/09/23	CI
First Amended Combined Liquidation Plan and Disclosure Statement Approved for PLx Pharma Winddown Corp.	14/09/23	CI
First Motion for Exclusivity Period Extension Approved For PLx Pharma Winddown Corp.	28/08/23	CI
First Motion for Exclusivity Period Extension Filed by PLx Pharma Winddown Corp.	10/08/23	CI
First Amended Disclosure Statement and Related Plan on Interim Basis Approved for PLx Pharma Winddown Corp.	28/07/23	CI
First Amended Combined Liquidation Plan and Disclosure Statement Filed by PLx Pharma Winddown Corp.	26/07/23	CI
Plx Pharma Winddown Corp. Announces Resignation of Natasha Giordano as Chief Executive Officer	07/07/23	CI
Plx Pharma Winddown Corp. Announces Resignation of Rita Oâ€™Connor as Chief Financial Officer	07/07/23	CI
Plx Pharma Winddown Corp. Announces Executive Changes	07/07/23	CI
Combined Disclousre Statement and Liquidation Plan Filed by PLx Pharma Winddown Corp.	07/07/23	CI
Motion for Asset Sale Approved for PLx Pharma Winddown Corp.	25/05/23	CI
Notice for Auction Cancellation Filed PLx Pharma Winddown Corp.	19/05/23	CI
Bidding Procedure Approved for PLx Pharma Inc.	10/05/23	CI
PLx Pharma Inc.(OTCPK:PLXP.Q) dropped from S&P TMI Index	17/04/23	CI
PLx Pharma Inc.(OTCPK:PLXP) dropped from S&P TMI Index	17/04/23	CI
Motion for Joint Administration Approved for PLx Pharma Inc.	14/04/23	CI
Motion for Asset Sale Filed by PLx Pharma Inc.	13/04/23	CI
Motion for Joint Administration Filed by PLx Pharma Inc.	13/04/23	CI
PLx Pharma Inc. Filed for Bankruptcy	13/04/23	CI
PLx Pharma Signs Stalking Horse Deal to Sell Assets to Greenwood Brands; Shares Jump After Hours	12/04/23	MT
Top Midday Decliners	12/04/23	MT
PLx Pharma Receives Notice of Delisting From Nasdaq	12/04/23	MT
PLx Pharma Inc.(OTCPK:PLXP) dropped from NASDAQ Composite Index	12/04/23	CI
PLx Pharma Inc.(OTCPK:PLXP) dropped from Russell Microcap Growth Index	12/04/23	CI
PLx Pharma Inc.(OTCPK:PLXP) dropped from Russell 3000E Growth Index	12/04/23	CI

Chart PLx Pharma Winddown Corp.

Duration

Period

More charts

Company Profile

PLx Pharma Winddown Corp., formerly PLx Pharma Inc., is a commercial-stage drug delivery platform technology company. The Company is focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent-protected PLxGuard technology. The Company has two Food and Drug Administration (FDA) approved products, VAZALORE 81 mg and VAZALORE 325 mg (VAZALORE), which are liquid-filled aspirin capsules for over-the-counter distribution (OTC). The Company markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation. It also screens additional compounds outside the NSAID category for possible development using its PLxGuard drug delivery platform.

Sector

More about the company